gamma-aminobutyric acid has been researched along with Central Nervous System Diseases in 43 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Central Nervous System Diseases: Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The study objective was to describe presenting pain behaviors, daily dose, and response to gabapentin for the management of frequent recurrent pain in this population." | 7.81 | Gabapentin for management of recurrent pain in 22 nonverbal children with severe neurological impairment: a retrospective analysis. ( Hauer, JM; Solodiuk, JC, 2015) |
| "A retrospective analysis was performed with data from 22 children with severe impairment of the CNS residing at a long-term care facility, treated with gabapentin for recurrent pain behaviors." | 7.81 | Gabapentin for management of recurrent pain in 22 nonverbal children with severe neurological impairment: a retrospective analysis. ( Hauer, JM; Solodiuk, JC, 2015) |
| "Gabapentin appears to be an effective treatment for children with severe impairment of the CNS and recurrent pain behaviors, including intermittent changes in muscle tone." | 7.81 | Gabapentin for management of recurrent pain in 22 nonverbal children with severe neurological impairment: a retrospective analysis. ( Hauer, JM; Solodiuk, JC, 2015) |
| "Gabapentin was administered orally in gradually increasing doses up to a maximum of 2,400 mg/day." | 6.69 | Effects of gabapentin on the different components of peripheral and central neuropathic pain syndromes: a pilot study. ( Attal, N; Bouhassira, D; Brasseur, L; Chauvin, M; Parker, F, 1998) |
| "Gabapentin appears to be an effective treatment for children with severe impairment of the CNS and recurrent pain behaviors, including intermittent changes in muscle tone." | 5.42 | Gabapentin for management of recurrent pain in 22 nonverbal children with severe neurological impairment: a retrospective analysis. ( Hauer, JM; Solodiuk, JC, 2015) |
| " Dosing information can guide treatment trials and future prospective studies." | 5.42 | Gabapentin for management of recurrent pain in 22 nonverbal children with severe neurological impairment: a retrospective analysis. ( Hauer, JM; Solodiuk, JC, 2015) |
| "The study objective was to describe presenting pain behaviors, daily dose, and response to gabapentin for the management of frequent recurrent pain in this population." | 3.81 | Gabapentin for management of recurrent pain in 22 nonverbal children with severe neurological impairment: a retrospective analysis. ( Hauer, JM; Solodiuk, JC, 2015) |
| "A retrospective analysis was performed with data from 22 children with severe impairment of the CNS residing at a long-term care facility, treated with gabapentin for recurrent pain behaviors." | 3.81 | Gabapentin for management of recurrent pain in 22 nonverbal children with severe neurological impairment: a retrospective analysis. ( Hauer, JM; Solodiuk, JC, 2015) |
| "Gabapentin appears to be an effective treatment for children with severe impairment of the CNS and recurrent pain behaviors, including intermittent changes in muscle tone." | 3.81 | Gabapentin for management of recurrent pain in 22 nonverbal children with severe neurological impairment: a retrospective analysis. ( Hauer, JM; Solodiuk, JC, 2015) |
| "Gabapentin was administered orally in gradually increasing doses up to a maximum of 2,400 mg/day." | 2.69 | Effects of gabapentin on the different components of peripheral and central neuropathic pain syndromes: a pilot study. ( Attal, N; Bouhassira, D; Brasseur, L; Chauvin, M; Parker, F, 1998) |
| "Olanzapine is an atypical antipsychotic agent, structurally related to clozapine, and extensively used for the treatment of schizophrenia, bipolar disorder-associated mania, and the behavioral symptoms of Alzheimer's disease." | 2.52 | Benzo- and thienobenzo- diazepines: multi-target drugs for CNS disorders. ( Botelho, SP; Da Silva, MS; Ishiki, H; Mendonça Júnior, FJ; Scotti, L; Scotti, MT, 2015) |
| "Gamma-aminobutyric acid is a major inhibitory neurotransmitter in the central nervous system." | 2.44 | [Gamma-aminobutyric acid--metabolism and its disorders]. ( Kowalski, A; Rebas, E; Zylińska, L, 2007) |
| "Gabapentin appears to be an effective treatment for children with severe impairment of the CNS and recurrent pain behaviors, including intermittent changes in muscle tone." | 1.42 | Gabapentin for management of recurrent pain in 22 nonverbal children with severe neurological impairment: a retrospective analysis. ( Hauer, JM; Solodiuk, JC, 2015) |
| " Dosing information can guide treatment trials and future prospective studies." | 1.42 | Gabapentin for management of recurrent pain in 22 nonverbal children with severe neurological impairment: a retrospective analysis. ( Hauer, JM; Solodiuk, JC, 2015) |
| "Gabapentin (Neurontin) is an antiepileptic drug commonly prescribed for pain treatment." | 1.35 | Prevalence of gabapentin in impaired driving cases in Washington State in 2003-2007. ( Peterson, BL, 2009) |
| "Several brain disorders, e." | 1.29 | Involvement of endogenous benzodiazepine receptor ligands in brain disorders: therapeutic potential for benzodiazepine antagonists? ( Polc, P, 1995) |
| "We studied the effects of GABA on anoxia-induced injury in CNS white matter using optic nerves exposed to 60 min of anoxia." | 1.29 | Endogenous GABA attenuates CNS white matter dysfunction following anoxia. ( Fern, R; Ransom, BR; Waxman, SG, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (16.28) | 18.7374 |
| 1990's | 8 (18.60) | 18.2507 |
| 2000's | 12 (27.91) | 29.6817 |
| 2010's | 16 (37.21) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Catavero, C | 1 |
| Bao, H | 1 |
| Song, J | 1 |
| Pelkey, KA | 1 |
| Chittajallu, R | 1 |
| Craig, MT | 1 |
| Tricoire, L | 1 |
| Wester, JC | 1 |
| McBain, CJ | 1 |
| Stahl, SM | 1 |
| Porreca, F | 1 |
| Taylor, CP | 1 |
| Cheung, R | 1 |
| Thorpe, AJ | 1 |
| Clair, A | 1 |
| Kumar, K | 1 |
| Sharma, S | 1 |
| Kumar, P | 1 |
| Deshmukh, R | 1 |
| Fritschy, JM | 1 |
| Hauer, JM | 1 |
| Solodiuk, JC | 1 |
| Mendonça Júnior, FJ | 1 |
| Scotti, L | 1 |
| Ishiki, H | 1 |
| Botelho, SP | 1 |
| Da Silva, MS | 1 |
| Scotti, MT | 1 |
| Hulse, G | 1 |
| Kelty, E | 1 |
| Hood, S | 1 |
| Norman, A | 1 |
| Basso, MR | 1 |
| Reece, AS | 1 |
| Jembrek, MJ | 1 |
| Vlainic, J | 1 |
| Gazulla, J | 1 |
| Ruiz-Gazulla, C | 1 |
| Tintore, M | 1 |
| Nascimento-Alves, P | 1 |
| Fernandes-Silva, H | 1 |
| Aragão-Homem, C | 1 |
| Geraldes, R | 1 |
| Fonseca, AC | 1 |
| Mittal, R | 1 |
| Debs, LH | 1 |
| Patel, AP | 1 |
| Nguyen, D | 1 |
| Patel, K | 1 |
| O'Connor, G | 1 |
| Grati, M | 1 |
| Mittal, J | 1 |
| Yan, D | 1 |
| Eshraghi, AA | 1 |
| Deo, SK | 1 |
| Daunert, S | 1 |
| Liu, XZ | 1 |
| Li, W | 1 |
| Zhou, M | 1 |
| Xu, N | 1 |
| Hu, Y | 1 |
| Wang, C | 1 |
| Li, D | 2 |
| Liu, L | 1 |
| Matias, M | 1 |
| Silvestre, S | 1 |
| Falcao, A | 1 |
| Alves, G | 1 |
| Kowalski, A | 1 |
| Rebas, E | 1 |
| Zylińska, L | 1 |
| Maciaczyk, J | 1 |
| Singec, I | 1 |
| Maciaczyk, D | 1 |
| Klein, A | 1 |
| Nikkhah, G | 1 |
| Peterson, BL | 1 |
| Kimelberg, HK | 1 |
| Nedergaard, M | 1 |
| Feuerstein, TJ | 1 |
| Kammerer, M | 1 |
| Lücking, CH | 1 |
| Moser, A | 1 |
| Allen, NJ | 1 |
| Káradóttir, R | 1 |
| Attwell, D | 1 |
| Fujimori, S | 1 |
| Yoneda, Y | 1 |
| Woo, NH | 1 |
| Lu, B | 1 |
| Taupin, P | 1 |
| Jagasia, R | 1 |
| Song, H | 1 |
| Gage, FH | 1 |
| Lie, DC | 1 |
| Vranken, JH | 1 |
| Dijkgraaf, MG | 1 |
| Kruis, MR | 1 |
| van der Vegt, MH | 1 |
| Hollmann, MW | 1 |
| Heesen, M | 1 |
| Claussen, CF | 1 |
| Grove, J | 1 |
| Tell, G | 1 |
| Schechter, PJ | 1 |
| Koch-Weser, J | 1 |
| Warter, JM | 1 |
| Marescaux, C | 1 |
| Rumbach, L | 1 |
| Bowser-Riley, F | 1 |
| Angel, A | 1 |
| Halsey, MJ | 2 |
| Little, H | 1 |
| Meldrum, BS | 1 |
| Ross, JA | 1 |
| Rostain, JC | 2 |
| Wardley-Smith, B | 2 |
| Enna, SJ | 2 |
| Kass, IS | 1 |
| Larsen, DA | 1 |
| Wang, CC | 1 |
| Stretton, AO | 1 |
| Polc, P | 1 |
| Fern, R | 1 |
| Waxman, SG | 1 |
| Ransom, BR | 1 |
| Gerster, H | 1 |
| Bloom, FE | 1 |
| Morales, M | 1 |
| Takayanagi, M | 1 |
| Ogawa, A | 1 |
| Attal, N | 1 |
| Brasseur, L | 1 |
| Parker, F | 1 |
| Chauvin, M | 1 |
| Bouhassira, D | 1 |
| Kontogiannis, V | 1 |
| Havlat, M | 1 |
| Lowe, JS | 1 |
| Powell, RJ | 1 |
| Alao, AO | 1 |
| Dewan, MJ | 1 |
| Tanganelli, S | 1 |
| Fuxe, K | 1 |
| Antonelli, T | 1 |
| O'Connor, WT | 1 |
| Ferraro, L | 1 |
| Wood, JH | 1 |
| Glaeser, BS | 1 |
| Hare, TA | 1 |
| Solimena, M | 1 |
| Folli, F | 1 |
| Aparisi, R | 1 |
| Pozza, G | 1 |
| De Camilli, P | 1 |
| Forni, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Efficacy of High-Dose Intravenous Immunoglobulin Therapy in Patients With Stiff-Man Syndrome: A Double-Blind, Placebo-Controlled Trial[NCT00001550] | Phase 1 | 20 participants | Interventional | 1996-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
21 reviews available for gamma-aminobutyric acid and Central Nervous System Diseases
| Article | Year |
|---|---|
Neural mechanisms underlying GABAergic regulation of adult hippocampal neurogenesis.
Topics: Adult; Animals; Central Nervous System Diseases; Dentate Gyrus; Disease Models, Animal; GABAergic Ne | 2018 |
Hippocampal GABAergic Inhibitory Interneurons.
Topics: Animals; Central Nervous System Diseases; GABAergic Neurons; gamma-Aminobutyric Acid; Hippocampus; H | 2017 |
The diverse therapeutic actions of pregabalin: is a single mechanism responsible for several pharmacological activities?
Topics: Animals; Calcium Channel Blockers; Central Nervous System Diseases; gamma-Aminobutyric Acid; Humans; | 2013 |
Therapeutic potential of GABA(B) receptor ligands in drug addiction, anxiety, depression and other CNS disorders.
Topics: Anxiety; Central Nervous System Diseases; Depression; GABA Modulators; gamma-Aminobutyric Acid; Huma | 2013 |
Benzo- and thienobenzo- diazepines: multi-target drugs for CNS disorders.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Central Nervous System; Central Nervous System Disea | 2015 |
Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System.
Topics: Animals; Central Nervous System; Central Nervous System Diseases; Flumazenil; GABA Antagonists; gamm | 2015 |
GABA Receptors: Pharmacological Potential and Pitfalls.
Topics: Animals; Binding Sites; Brain; Central Nervous System Diseases; Drug Design; GABA Agents; gamma-Amin | 2015 |
GABAergic Pharmacotherapy in the Treatment of Motor Disorders of the Central Nervous System.
Topics: Adult; Animals; Central Nervous System Diseases; Cerebellar Ataxia; GABA Agents; gamma-Aminobutyric | 2015 |
Neurotransmitters: The Critical Modulators Regulating Gut-Brain Axis.
Topics: Adenosine Triphosphate; Animals; Bacteria; Brain; Catecholamines; Central Nervous System Diseases; E | 2017 |
Recent Highlights on Molecular Hybrids Potentially Useful in Central Nervous System Disorders.
Topics: Analgesics; Central Nervous System Diseases; Choline; Donepezil; Epilepsy; gamma-Aminobutyric Acid; | 2017 |
[Gamma-aminobutyric acid--metabolism and its disorders].
Topics: Anxiety Disorders; Central Nervous System Diseases; Fatigue Syndrome, Chronic; gamma-Aminobutyric Ac | 2007 |
Functions of astrocytes and their potential as therapeutic targets.
Topics: Animals; Antioxidants; Aquaporin 4; Astrocytes; Central Nervous System Diseases; Complex Mixtures; g | 2010 |
Selective GABA release as a mechanistic basis of high-frequency stimulation used for the treatment of neuropsychiatric diseases.
Topics: Animals; Central Nervous System Diseases; Deep Brain Stimulation; gamma-Aminobutyric Acid; Glutamic | 2011 |
Reversal or reduction of glutamate and GABA transport in CNS pathology and therapy.
Topics: Acute Disease; Animals; Central Nervous System Diseases; Chronic Disease; gamma-Aminobutyric Acid; G | 2004 |
[Neuropsychiatric disorders and GABA].
Topics: Central Nervous System Diseases; gamma-Aminobutyric Acid; Humans; Mental Disorders; Signal Transduct | 2004 |
Regulation of cortical interneurons by neurotrophins: from development to cognitive disorders.
Topics: Animals; Central Nervous System Diseases; Cerebral Cortex; Cognition Disorders; gamma-Aminobutyric A | 2006 |
Neurogenesis in the adult central nervous system.
Topics: Animals; Brain; Central Nervous System; Central Nervous System Diseases; gamma-Aminobutyric Acid; Hu | 2006 |
[The importance of vitamin B 6 for development of the infant. Human medical and animal experiment studies].
Topics: Animals; Central Nervous System; Central Nervous System Diseases; Dopamine; Female; gamma-Aminobutyr | 1996 |
The central 5-HT3 receptor in CNS disorders.
Topics: Animals; Brain; Central Nervous System Diseases; gamma-Aminobutyric Acid; Humans; Models, Neurologic | 1998 |
[D-2-hydroxyglutaric aciduria].
Topics: Biomarkers; Cardiomyopathy, Dilated; Central Nervous System Diseases; Diagnosis, Differential; gamma | 1998 |
Cholecystokinin/dopamine/GABA interactions in the nucleus accumbens: biochemical and functional correlates.
Topics: Animals; Central Nervous System Diseases; Cholecystokinin; Dopamine; gamma-Aminobutyric Acid; Humans | 2001 |
2 trials available for gamma-aminobutyric acid and Central Nervous System Diseases
| Article | Year |
|---|---|
Pregabalin in patients with central neuropathic pain: a randomized, double-blind, placebo-controlled trial of a flexible-dose regimen.
Topics: Central Nervous System Diseases; Double-Blind Method; Female; gamma-Aminobutyric Acid; Humans; Male; | 2008 |
Effects of gabapentin on the different components of peripheral and central neuropathic pain syndromes: a pilot study.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Central Nervous System Diseases; Cyclohexanecarboxyli | 1998 |
20 other studies available for gamma-aminobutyric acid and Central Nervous System Diseases
| Article | Year |
|---|---|
Significance of GABA(A) receptor heterogeneity: clues from developing neurons.
Topics: Animals; Benzodiazepines; Brain; Central Nervous System Diseases; gamma-Aminobutyric Acid; Humans; L | 2015 |
Gabapentin for management of recurrent pain in 22 nonverbal children with severe neurological impairment: a retrospective analysis.
Topics: Adolescent; Adult; Amines; Analgesics; Central Nervous System Diseases; Child; Child, Preschool; Cyc | 2015 |
IV and V cranial nerves dysfunction as initial manifestations of superficial siderosis of the central nervous system.
Topics: Aged; Amines; Angiography, Digital Subtraction; Atrophy; Central Nervous System Diseases; Cerebellum | 2016 |
Comparative analysis of protective effects of curcumin, curcumin-β-cyclodextrin nanoparticle and nanoliposomal curcumin on unsymmetrical dimethyl hydrazine poisoning in mice.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; beta-Cyclodextrins; Central Nervous Syst | 2016 |
Restricted spontaneous in vitro differentiation and region-specific migration of long-term expanded fetal human neural precursor cells after transplantation into the adult rat brain.
Topics: Animals; Brain; Cell Differentiation; Cell Movement; Central Nervous System Diseases; Doublecortin P | 2009 |
Prevalence of gabapentin in impaired driving cases in Washington State in 2003-2007.
Topics: Accidents, Traffic; Adult; Aged; Amines; Anticonvulsants; Automobile Driving; Central Nervous System | 2009 |
New regulators in adult neurogenesis and their potential role for repair.
Topics: Animals; Central Nervous System Diseases; gamma-Aminobutyric Acid; Hippocampus; Humans; Mice; Neuron | 2006 |
The slow-brainstem syndrome: tinnitus and dyssynchrony in the central nervous system.
Topics: Auditory Pathways; Brain Stem; Central Nervous System Diseases; gamma-Aminobutyric Acid; Histamine; | 2007 |
Increased CSF gamma-aminobutyric acid after treatment with gamma-vinyl GABA.
Topics: 4-Aminobutyrate Transaminase; Aminocaproates; Brain Chemistry; Central Nervous System Diseases; gamm | 1980 |
Mechanistic studies on the high pressure neurological syndrome.
Topics: Animals; Atmospheric Pressure; Biogenic Amines; Biomechanical Phenomena; Central Nervous System Dise | 1984 |
Specific effects of drugs at pressure: animal investigations.
Topics: Amino Acids; Anesthetics; Animals; Anticonvulsants; Atmospheric Pressure; Catecholamines; Central Ne | 1984 |
GABA and neuropsychiatric disorders.
Topics: Animals; Basal Ganglia; Central Nervous System Diseases; Epilepsies, Myoclonic; Epilepsies, Partial; | 1980 |
Ascaris suum: differential effects of avermectin B1a on the intact animal and neuromuscular strip preparations.
Topics: Acetylcholine; Antinematodal Agents; Ascaris; Central Nervous System Diseases; gamma-Aminobutyric Ac | 1982 |
Involvement of endogenous benzodiazepine receptor ligands in brain disorders: therapeutic potential for benzodiazepine antagonists?
Topics: Animals; Benzodiazepines; Brain Diseases; Central Nervous System Diseases; gamma-Aminobutyric Acid; | 1995 |
Endogenous GABA attenuates CNS white matter dysfunction following anoxia.
Topics: Animals; Axons; Baclofen; Central Nervous System Diseases; Enzyme Activation; Female; gamma-Aminobut | 1995 |
Lesson of the month: Systemic vasculitis or not? That is the question.
Topics: Acetates; Amines; Anticoagulants; Anticonvulsants; Brain; Carbamazepine; Central Nervous System Dise | 1999 |
Evaluating the tolerability of the newer mood stabilizers.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Central Nervous System Diseases; Cyclohexanecar | 2001 |
Verification and quantification of GABA in human cerebrospinal fluid.
Topics: Aminobutyrates; Central Nervous System Diseases; Chromatography, Ion Exchange; Fluorometry; gamma-Am | 1978 |
Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome.
Topics: Autoantibodies; Autoantigens; Autoimmune Diseases; Brain; Central Nervous System Diseases; Cerebrosp | 1990 |
Gamma-aminobutyric acid and the high pressure neurological syndrome.
Topics: Alanine; Aminobutyrates; Animals; Atmospheric Pressure; Central Nervous System Diseases; Electrodes, | 1986 |